Molecular basis of two novel and related high-prevalence antigens in the Kell blood group system, KUCI and KANT, and their serologic and spatial association with K11 and KETI

Transfusion

Volumn 53, Issue 11 PART 2, 2013, Pages 2872-2881

  Velliquette, Randall W ^b   Hue Roye, Kim ^b   Lomas Francis, Christine ^b   Gillen, Barbara ^b   Schierts, Jennifer ^b   Gentzkow, Kristie ^b   Peyrard, Thierry ^b   Von Zabern, Inge ^b   Flegel, Willy A ^b   Rodberg, Karen ^b   Debnath, Asim K ^b   Lee, Soohee ^b   Reid, Marion E ^a  

^a NEW YORK BLOOD CENTER   (United States)

^b INSTITUT NATIONAL DE LA TRANSFUSION SANGUINE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BLOOD GROUP KELL SYSTEM; BLOOD TRANSFUSION; ERYTHROCYTE; FEMALE; GENE FREQUENCY; GENETICS; GENOTYPE; HUMAN; IMMUNOLOGY; MALE; MIDDLE AGED; MISSENSE MUTATION; MOLECULAR GENETICS; PEDIGREE; SEROLOGY; TISSUE DISTRIBUTION;

ADULT; BLOOD TRANSFUSION; ERYTHROCYTES; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; KELL BLOOD-GROUP SYSTEM; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION, MISSENSE; PEDIGREE; SEROLOGIC TESTS; TISSUE DISTRIBUTION;

BLOOD GROUP KELL SYSTEM;

EID: 84893367362     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.12200     Document Type: Article

References (43)

1. Lee S. Molecular basis of Kell blood group phenotypes. Vox Sang 1997;73: 1-11.
2. Lee S, Russo D, Redman CM. The Kell blood group system: Kell and XK membrane proteins. Semin Hematol 2000;37: 113-21.
3. Lee S, Debnath AK, Wu X, Scofield T, George T, Kakaiya RM, Yogore MG, III, Sausais L, Yacob M, Lomas-Francis C, Reid ME. Molecular basis of two novel high prevalence antigens in the Kell blood group system, KALT and KTIM. Transfusion 2006;46: 1323-7.
4. Uchikawa M, Onodera T, Ogasawara K, Tsuneyama H, Toyoda C, Yabe R, Enomoto T, Satake M, Nakajima K. Molecular basis for a novel low-frequency antigen in the Kell blood group system, KYO [abstract]. Vox Sang 2006;91 Suppl 3:136.
5. Karamatic Crew V, Poole J, Watson T, Bullock T, Burton N, Daniels G. KASH (KEL34): a novel high incidence antigen in the Kell blood group system [abstract]. Vox Sang 2010;99 Suppl 1:357.
6. Karamatic Crew V, Poole J, Bullock T, Malde R, Burton N, Daniels G. KELP (KEL35): a new high incidence antigen in the Kell blood group defined by two homozygous missense mutations in KEL [abstract]. Transfus Med 2010;20 Suppl 1:30.
7. Karamatic Crew V, Poole J, Bullock T, Regan P, Burton N, Daniels G. KETI, a novel high incidence antigen in the Kell blood group system: a serological and molecular study [abstract]. Vox Sang 2011;101 Suppl 1:19.
8. Vege S, Lomas-Francis C, Velliquette RW, Rodberg K, Bailey D, Horn T, Westhoff CM. A new high prevalence antigen (KHUL) in the Kell blood group system [abstract]. Transfusion 2011;51 Suppl:25A-6A.
9. Lomas-Francis C, Fuuchiswa A, Uchikawa M, Tani Y, Vege S, Westhoff CW. A new high prevalence Kell antigen KYOR, antithetical to the low-prevalence antigen KYO, is the second trypsin-senstive Kell antigen. Transfusion 2012;52 Suppl:158A-9A.
10. Reid ME, Lomas-Francis C, Olsson ML. The blood group antigen factsbook. 3rd ed. Waltham, MA: Elsevier; 2012.
11. Lee S, Zambas ED, Marsh WL, Redman CM. Molecular cloning and primary structure of Kell blood group protein. Proc Natl Acad Sci U S A 1991;88: 6353-7.
12. Ho M, Chelly J, Carter N, Danek A, Crocker P, Monaco AP. Isolation of the gene for McLeod syndrome that encodes a novel membrane transport protein. Cell 1994;77: 869-80.
13. Lee S, Lin M, Mele A, Cao Y, Farmar J, Russo D, Redman C. Proteolytic processing of big endothelin-3 by the Kell blood group protein. Blood 1999;94: 1440-50.
14. Lee S, Russo D, Redman C. Functional and structural aspects of the Kell blood group system. Transfus Med Rev 2000;14: 93-103.
15. Lee S, Reid ME, Redman CM. Point mutations in KEL exon 8 determine a high incidence (RAZ) and a low incidence (KEL25, VLAN) antigen of the Kell blood group system. Vox Sang 2001;81: 259-63.
16. Lee S. The value of DNA analysis for antigens of the Kell and Kx blood group systems. Transfusion 2007;47 Suppl: 32S-9S.
17. Daniels G, Castilho L, Flegel WA, Fletcher A, Garratty G, Levene C, Lomas-Francis C, Moulds JM, Moulds JJ, Olsson ML, Overbeeke M, Poole J, Reid ME, Rouger P, van der Schoot E, Scott M, Sistonen P, Smart E, Storry JR, Tani Y, Yu LC, Wendel S, Westhoff C, Yahalom V, Zelinski T. International Society of Blood Transfusion Committee on terminology for red cell surface antigens: Macao report. Vox Sang 2009;96: 153-6.
18. Storry JR, Castilho L, Daniels G, Flegel WA, Garratty G, Francis CL, Moulds JM, Moulds JJ, Olsson ML, Poole J, Reid ME, Rouger P, van der Schoot E, Scott M, Smart E, Tani Y, Yu LC, Wendel S, Westhoff C, Yahalom V, Zelinski T. International Society of Blood TransfusionWorking Party on red cell immunogenetics and blood group terminology: Berlin report. Vox Sang 2011;101: 77-82.
19. Poole J, Warke N, Hustinx H, Taleghani BM, Martin P, Finning K, Crew VK, Green C, Bromilow I, Daniels G. A KEL gene encoding serine at position 193 of the Kell glycoprotein results in expression of KEL1 antigen. Transfusion 2006;46: 1879-85.
20. Lee-Stroka H, Slezak SL, Adams S, Martin J, Robbins FM, Caruccio L, Byrne KM, Stroncek DF. Another example of a KEL1 variant red cell phenotype due to a threonine to serine change at position 193 of Kell glycoprotein. Transfusion 2008;48: 925-9.
21. Uchikawa M, Onodera T, Tsuneyama H, Enomoto T, Ishijima A, Yuasa S, Murata S, Tadokoro K, Nakajima K, Juji T. Molecular basis of unusual Kmod phenotype with K+wk- [abstract]. Vox Sang 2000;78 Suppl 1:0011.
22. Øyen R, Halverson GR, Reid ME. Review: conditions causing weak expression of Kell system antigens. Immunohematology 1997;13: 75-9.
23. Kormoczi GF, Scharberg EA, Gassner C. A novel KEL*1,3 allele with weak Kell antigen expression confirming the cis-modifier effect of KEL3. Transfusion 2009;49: 733-9.
24. Kormoczi GF, Wagner T, Jungbauer C, Vadon M, Ahrens N, Moll W, Muhlbacher A, Ozgul-Gulce S, Kleinrath T, Kilga-Nogler S, Schonitzer D, Gassner C. Genetic diversity of KELnull and KELel: a nationwide Austrian survey. Transfusion 2007;47: 703-14.
25. Lee S, Russo DC, Reiner AP, Lee JH, Sy MY, Telen MJ, Judd WJ, Simon P, Rodrigues MJ, Chabert T, Poole J, Jovanovic-Srzentic S, Levene C, Yahalom V, Redman CM. Molecular defects underlying the Kell null phenotype. J Biol Chem 2001;276: 27281-9.
26. Schulz H, Dale GE, Karimi-Nejad Y, Oefner C. Structure of human endothelin-converting enzyme I complexed with phosphoramidon. J Mol Biol 2009;385: 178-87.
27. Judd WJ, Johnson ST, Storry Jr. Judd's methods in immunohematology. 3rd ed. Bethesda (MD): American Association of Blood Banks; 2008.
28. Mallory D. Immunohematology methods and procedures. Rockville (MD): American Red Cross; 1993.
29. Pieper U, Webb BM, Barkan DT, Schneidman-Duhovny D, Schlessinger A, Braberg H, Yang Z, Meng EC, Pettersen EF, Huang CC, Datta RS, Sampathkumar P, Madhusudhan MS, Sjolander K, Ferrin TE, Burley SK, Sali A. ModBase, a database of annotated comparative protein structure models, and associated resources. Nucleic Acids Res 2011;39:D465-74.
30. Eswar N, John B, Mirkovic N, Fiser A, Ilyin VA, Pieper U, Stuart AC, Marti-Renom MA, Madhusudhan MS, Yerkovich B, Sali A. Tools for comparative protein structure modeling and analysis. Nucleic Acids Res 2003; 31: 3375-80.
31. Sali A, Blundell TL. Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol 1993;234: 779-815.
32. Oefner C, Roques BP, Fournie-Zaluski MC, Dale GE. Structural analysis of neprilysin with various specific and potent inhibitors. Acta Crystallogr D 2004;60: 392-6.
33. Laskowski RA, MacArthur MW, Moss DS, Thornton JM. PROCHECK - a program to check the stereochemical quality of protein structures. J Appl Crystallogr 1993;26: 283-91.
34. Hooft RW, Vriend G, Sander C, Abola EE. Errors in protein structures. Nature 1996;381:272.
35. Eisenberg D, Luthy R, Bowie JU. VERIFY3D: assessment of protein models with three-dimensional profiles. Methods Enzymol 1997;277: 396-404.
36. Prokop M, Adam J, Kriz Z, Wimmerova M, Koca J. TRITON: a graphical tool for ligand-binding protein engineering. Bioinformatics 2008;24: 1955-6.
37. Tina KG, Bhadra R, Srinivasan N. PIC: protein interactions calculator. Nucleic Acids Res 2007;35:W473-6.
38. Lee S, Wu X, Son S, Naime D, Reid M, Okudo Y, Sistonen P, Redman C. Point mutations characterize KEL10, the KEL3, KEL4, and KEL21 alleles, and the KEL17 and KEL11 alleles. Transfusion 1996;36: 490-4.
39. Velliquette RW, Sausais L, Lomas-Francis C, Wu X, Lee S, Reid ME, Gillen B, Beatty CE, Thomas R, Schierts JD, Gentzkow K, Schafer J, Reinke D. Two novel and related high-prevalence antigens in the Kell blood group system [abstract]. Transfusion 2007;47 Suppl:164A-5A.
40. Lee S, Russo DC, Reid ME, Redman CM. Mutations that diminish expression of Kell surface protein and lead to the Kellmod red cell phenotype. Transfusion 2003;43: 1121-5.
41. Moulds JM, Persa R, Hue-Roye K, Reid ME. Characterization of the first K0 with anti-Ku found in an Apache Indian [abstract]. Transfusion 2011;51 Suppl:135A.
42. Arnaud L, Helias V, Menanteau C, Peyrard T, Lucien N, Ripoche P, Lapegue R, Pham BN, Le Pennec PY, Moulds JJ, Cartron JP. A functional AQP1 allele producing a Co(a-b-) phenotype revises and extends the Colton blood group system. Transfusion 2010;50: 2106-16.
43. Yazdanbakhsh K, Lee S, Yu Q, Reid ME. Identification of a defect in the intracellular trafficking of a Kell blood group variant. Blood 1999;94: 310-8.